Oxford BioDynamics (LON:OBD) Hits New 1-Year Low – What’s Next?

Oxford BioDynamics Plc (LON:OBD) hit a new 52-week low on Monday . The company traded as low as GBX 0.22 and last traded at GBX 0.23, with a volume of 8472889 shares changing hands. The stock had previously closed at GBX 0.23.

Analyst Upgrades and Downgrades

Separately, Shore Capital restated a “house stock” rating on shares of Oxford BioDynamics in a research note on Wednesday, October 8th.

Oxford BioDynamics Stock Performance

The company has a market cap of £9.44 million, a P/E ratio of -0.08 and a beta of 0.42. The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22. The business has a fifty day simple moving average of GBX 0.27 and a two-hundred day simple moving average of GBX 0.39.

Oxford BioDynamics (LON:OBD) last released its quarterly earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.